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A B S T R A C T
Background: Syncephalastrum species belong to the class Zygomycetes and order Mucorale. These are
found in the environment and tropical soil, usually presenting as colonizers and rarely cause human
infection. Syncephalastrum racemosum is a species of the genus Syncephalastrum and is the most
commonly identified pathogen. Most cases are reported in immunocompromised individuals, such as
patients on long term steroids, poorly controlled diabetes, or patients with malignancy.
Case presentation: We are describing two cases of rare fungal infection by Syncephalastrum species
causing invasive pulmonary manifestation. Both patients had compromised immune status and
presented with worsening dyspnea to the emergency room. Both had signs and symptoms of bilateral
worsening pneumonia evident by chest X-ray showing bilateral pulmonary infiltrates. Syncephalastrum
species were isolated from sputum cultures. Deoxycholate amphotericin B was started and the response
was monitored. One patient expired while the other improved. Syncephalastrum species belong to class
Mucormycosis, rarely causing invasive infection but when they do outcome is potentially fatal. Very few
cases are reported worldwide so the clinical course is still unclear. To the best of our knowledge, these are
the first two cases to be reported from Pakistan.
Conclusions: These two cases describe pneumonia as a result of concomitant infection by rare fungal
speciesSyncephalastrumand MRSA in immunocompromised patients. Fewcases are reportedso limiteddata
is available to understand completedisease implications. Mucormycosis is a therapeuticchallenge because
of the phylogenetic diversity, un-availability of any serological testing and invasive disease pattern.
© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Mucormycosis also known as Zygomycosis is infection with a
class of fungi including three orders, the largest of them is
Mucorales. The most common species of this order are Rhizopus
and Mucor [3] but there are certain rare species such as
Syncephalastrum. These are often responsible for opportunistic
fungal infections in immunocompromised patients [13]. Synce-
phalastrum racemosum, the species of the genus Syncephalastrum
species is potentially fatal to human beings. Although usually
resulting in cutaneous infections and onychomycosis, there have
been few case reports of respiratory and CNS infections in
immunocompromised hosts [14]. Since this is a rare entity, hardly
any data is available on treatment response to different antifungal
agents. However recent improvements in diagnostic strategies
result in early identification and treatment. Amphotericin B is the
drug of choice due to its low MICs [15]. We are describing these
cases to emphasize the importance of considering rare fungal
infections in the differential diagnosis of an immunocompromised




A 55-year-old South Asian gentleman recently diagnosed with
Acute Myeloid Leukemia, not on treatment, presented to the
emergency room with one day history of severe shortness of
Abbreviations: MRSA, Multi drug resistant Staphylococcus aureus; IV, intrave-
nous; COPD, chronic obstructive pulmonary disease; CT, Computed Tomography;
MIC, Minimum inhibitory concentration; VATS, video assisted thoracic surgery.
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breath, fever, and scanty sputum production. On examination he
was found to be hypoxic with oxygen saturation (SaO2) of 90 % on
room air, hypotensive with pressures of 90/60 mmHg, temperature
of 38 C, tachycardia with a pulse rate of 102/min, and bilateral
coarse crepitations on auscultation. Chest X-ray (Fig. 1) showed
bilateral infiltrates. In view of his recent hospitalization, he was
provisionally diagnosed with hospital-acquired pneumonia and
was started on empirical piperacillin/tazobactam. However, based
on his sputum culture showing Methicillin Resistant Staphylococ-
cus aureus (MRSA) and Syncephalastrum species, deoxycholate
amphotericin B and vancomycin were introduced in the regimen
resulting in a gradual reduction of white blood counts from 23 
109/L (17 % blast cells) to 10.7  109/L. Histopathology or tissue
sampling was not performed in this patient. The patient improved
initially but after 8 days of therapy, he developed acute kidney
injury, hypotension and severe lactic acidosis. Both drugs were
adjusted according to a creatinine clearance of 10 mL/min;
deoxycholate amphotericin B 1 mg/kg/day was reduced to 0.5
mg/kg/day and vancomycin was adjusted to keep trough levels
between 1020 mg/L. The patient gradually improved on
treatment but subsequently deteriorated as evident by declining
creatinine clearance on day 8. A progression of his primary disease
was thought to be an accelerating factor. He developed metabolic
and respiratory acidosis and was intubated on day 12 and
hemodialysis was planned but he expired after 12 days of
admission (after receiving 10 days of deoxycholate amphotericin
B and vancomycin).
Case 2
A 73-year-old gentleman, known patient of chronic obstructive
pulmonary disease (COPD), on tablet prednisolone 5 mg for the
past one month (after a recent tapering from 30 mg/day) and
inhaled salmeterol with fluticasone 25/250 mcg for almost 3 years.
He presented with gradually worsening shortness of breath for one
week in the emergency room. He had mucoid sputum production
but no fever. On presentation, he had SaO2 of 88 % on room air, with
low pressures of 100/60 mmHg, no fever, and a pulse rate of 90/
min. He also had bilateral crepitations associated with a wheeze.
Chest X-ray and CT chest (Figs. 2 and 3 respectively) showed
infiltrates and cavity formation. The total leucocyte count on
presentation was 18.2  109/L. The patient was started empirically
on piperacillin/tazobactam and vancomycin. Later, therapy was
switched to deoxycholate amphotericin B, and vancomycin was
continued according to his culture which grew MRSA, Aspergillus flavus, and Syncephalastrum species. Both A. flavus and Syncepha-
lastrum spp. were identified on gross and microscopic morphology.
Identification to genus level was performed for Syncephalastrum
spp. as speciation was not possible with available laboratory
capacity.
Serum Beta D glucan level performed on day 5 of admission was
62.14 pg/mL, where levels <60 pg/ml were considered negative,
6080 pg/ml borderline, and >80 pg/ml as positive as per
manufacturer [Fungitell (Cape Cod, USA)]. Serum Aspergillus
galactomannan index [Platiella (Biorad, France)] sent on the same
day was 0.26, where a single value of >0.7 or two consecutive
samples with a value of >0.5 were considered positive while a
value <0.5 was deemed negative. The patient’s creatinine
clearance declined to 27 mL/min after 7 days of therapy so doses
were adjusted by reducing deoxycholate amphotericin B to 0.8 mg/
kg/day from 1 mg/kg/day and trough levels for vancomycin were
maintained between 1020 mg/L. After 8 days of therapy on
adjusted doses, the patient suddenly developed tachypnea,
hypoxia, and hypotension. CT chest showed empyema so
emergency video-assisted thoracic surgery (VATS) with decortica-
tion was performed. Chest tubes were also placed. Histopathology
of pleural tissue performed showed moderate acute and chronicFig. 1. Chest X-ray. First X-ray of Case 1 on presentation.
Fig. 2. Chest X-ray. First X-ray of Case 2 on presentation.
Fig. 3. CT Scan chest. Pretreatment Scan of Case 2 showing infiltrates and cavity
formation.
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inflammatory cells with no evidence of granuloma formation or
malignancy in the available material. Although gram stain and PAF
were not performed on paraffin-embedded tissue sections, the
sample was also sent to Microbiology for smear and culture. Gram
stain of the tissue performed showed only gram positive cocci and
cultures grew MRSA. No fungal culture was sent at that time. Acid-
fast stain, GeneXpert MTB/RIF, and mycobacterial cultures were
later reported negative. The patient received vancomycin and
deoxycholate amphotericin B for MRSA and Syncephalastrum
pneumonia for two weeks. He improved clinically after the
surgery and was discharged after 44 days of stay on oral
voriconazole as subsequent cultures grew Aspergillus flavus.
Vancomycin was switched to oral linezolid with an early follow-
up. His chest X-ray improved (Fig. 4) on day 50 of therapy. The
patient was advised regular follow-ups. He eventually got better
after 6 weeks of outpatient therapy. He was treated for total twelve
weeks (including both in- and out-patient duration).
The diagnosis was made in both cases after the sputum culture
reports were finalized, but at the initial presentation the
differential diagnosis, keeping in view the immune status and
recent hospitalization, included viral pneumonia, atypical and
multi drug-resistant bacterial pneumonia, fungal pneumonia as
with Pneumocystis jiroveci, and primary disease progression. In
both cases, diagnosis of co-infection with MRSA and Syncephalas-
trum was considered.
Both cases were treated with deoxycholate amphotericin B,
case 1 for 10 days, and case 2 for two weeks. In both cases,
deoxycholate amphotericin led to acute kidney injury. However, in
case 2, follow-up sputum cultures were sent 26 days after the the
initial positive culture which came out negative for fungi. Due to
limited data present and unavailability of management guidelines,
it is unclear whether the negative culture report depicted that two
weeks were sufficient enough for treatment or that the pathogen
was a contaminant. A third sputum sample for culture sent at 34
days grew Aspergillus flavus, so voriconazole alone was continued
for the next 6 weeks.
Discussion
Syncephalastrum species belong to the class Zygomycetes and
order Mucorale [1]. These are found in the environment, and
tropical soil [2] and usually present as colonizers [12] and rarely
cause human infection [1,5]. When clinically significant, they are
usually implicated in cutaneous infections and onychomycosis
[3,11]. Very few cases are reported involving sites other than skin
and nail tissues. Syncephalastrum species rarely result in pneumo-
nia or a fungal ball like Aspergillus species [8]. Syncephalastrum
racemosum belongs to genus Syncephalastrum and is the most
commonly identified pathogen in this genus [4]. It has ribbon-like
aseptate, branched fungal hyphae and sporangiophores, which
terminate in swollen vesicles with radial merosporangiae filled
with spores [6]. This pathogen formed light greyish-white fluffy
colonies which filled a 90 mm plate completely in 48 h. Reverse
was grey white. The colonies later became dark brown due to
sporulation. Most cases are reported in immunocompromised
individuals (Table 1), e.g. patients on long term steroids, poorly
controlled diabetes [9], or patients with malignancy [13]. These
patients are at high risk of developing an infection [7] and the
combination of compromised immune status with a fungal
infection, no doubt has a high mortality. Like other species of
Mucormycosis, Syncephalastrum can also cause rhino-cerebral or
rhino-orbital-cerebral infection [10]. Only one case with intra-
abdominal infection is reported [14]. Syncephalastrum racemosum
closely mimics Aspergillus in microscopy due to its vesicle
surrounded by radially arranged sporangia, and is likely to be
misidentified. Even when recognized correctly, since it is usually a
contaminant, a high index of suspicion and systematic approach in
accurate diagnosis is needed to establish its clinical significance for
the successful outcome of treatment [3]. The only effective
treatment option available is amphotericin B or posaconazole
but possibly not isavuconazole/ ravuconazole [17]. Early identifi-
cation and initiation of therapy is the mainstay of improved clinical
outcome. Apart from these, the immune status of patients also
helps in determining the prognosis.
These two cases describe pneumonia as a result of concomitant
infection by rare fungal species Syncephalastrum and MRSA in
immunocompromised patients.
Few cases are reported so limited data is available to
understand complete disease implications. Only two cases of lung
infection leading to pneumonia were reported and even in those
the management strategy used was variable and unclear. In our
case report; case 1 had untreated malignancy and repeated
hospital encounters, similar to another case report with Non-
Hodgkin’s Lymphoma patient. In both our and their cases, patients
expired suggesting the invasiveness of this pathogen, but the
natural disease course was not fully understood. In case 2, in
contrast to available case reports, patients with COPD with acute
pneumonia and on long-term steroids but otherwise healthy was
also managed on the lines of probable pulmonary mucormycosis
with co-infection. Keeping in account the acuity of his illness,
Aspergillus in repeat culture might not be the only answer to his
condition. In one case report, a combination treatment strategy
was also used, so azoles may show some efficacy against
Syncephalastrum spp. if used in combination. However, since
repeat cultures were sent late and after two weeks of amphotericin
therapy, we still are not sure about the actual pathogens involved
in the disease process. More substantial evidence is needed to
conclude the definitive treatment strategy and management
protocol. For now, management plan for mucormycosis is no
doubt a therapeutic challenge because of the phylogenetic
diversity, unavailability of any serological testing and invasive
disease pattern. So far management strategy is individualized for
every case, so till any specific guidelines are devised, every case is
worth reporting.
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Table 1
Review of previous case reports.
Case report authors Sites involved Co morbid Management outcome
Sabitha B. et al [3] Nails - onychomycosis Diabetic Surgical debridement + nystatin Survived
Kamalam A. et al [7] Nails - onychomycosis Diabetic Local debridement Died of other complications
Kirkpatrick MB. Et al [8] Lung – – Unknown
Mangaraj S [9] Subcutaneous tissue Diabetic Surgical debridement + Amphotericin B Survived
Pavlovic MD [12] Nails-onychomycosis Immune competent Nail plate avulsion + nystatin Survived
Mathuram AJ [10] Rhino-orbito cerebral Diabetes Amphotericin B Unknown
Rodriguez-Gutierrez G [12] Lung Non-Hodgkin’s lymphoma Amphotericin-B itraconazole, caspofungin,
voriconazole + surgical resection
Died
Schlebusch S. et al [14] Intra-abdominal collection Immune competent Surgical debridement + Amphotericin B Survived
Arunava k. et al [16] Ear Diabetic Surgical debridement + Amphotericin B Survived
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